A new Lancet Oncology Commission highlights a growing "human crisis" in cancer care. Despite advances in treatment and ...

Longer-term trial results show Voranigo may help control grade 2 IDH-mutated glioma after surgery for those who can delay ...

Androgen receptor pathway inhibitors (ARPIs) in combination with androgen deprivation therapy (ADT) represent the foundation ...

Vorasidenib significantly improved median progression-free survival and time to next intervention in IDH-mutant grade 2 ...

"These longer-term results from the INDIGO trial build upon VORANIGO's previously demonstrated clinical benefits and ...

While AI advancements like 3D tumor auto-segmentation and radiation therapy planning have been FDA-approved for adult oncology, pediatric standards were lacking. The AI-RAPNO policy and its companion ...

News involving the treatment of multiple myeloma this year was highlighted by talk of a potential cure with a single infusion ...

On Oct 8, 2025, a new law was introduced in British Columbia, Canada, that, if passed, will take action against e-cigarette ...

While most of what the FDA laid out in a recent draft guidance on the assessment of overall survival in oncology clinical ...

Akeso Inc. (9926.HK) today announced that the groundbreaking results from the registrational Phase III AK112-306/HARMONi-6 study of ivonescimab have been accepted for publication in The Lancet. The ...

Last week, Lancet Oncology released a special report, "Future Cancer Research Priorities in the USA: A Lancet Oncology Commission." As co-author of this report, I joined fellow cancer research experts ...

An international clinical study led by the Medical University of Vienna shows that the drug patritumab deruxtecan (HER3-DXd) can have a promising effect in patients with active brain metastases of ...